InMed Pharmaceuticals Inc. (INM) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to NMED Pharmaceutical's fourth quarter fiscal 2022 financial results and business update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Colin Clancy, Vice President of Investor Relations. Please go ahead. Thank you, Norma, and good day, ladies and gentlemen. My name is Colin Clancy, INMED's Vice President of Investor Relations. Welcome to INMED's fiscal year and 2022 financial results and business update conference call. Please note our speakers are joining today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges. Before we begin, we would like to go over our disclosure statements, followed by a progress report on our Pharmaceutical Drug Development Program, led by our President and CEO, Eric Adams, together with an update on our health and wellness commercial activities, which will be provided by Michael Woodenberg, our Chief Operating Officer. Ms. Brenda Edwards, our Interim Chief Financial Officer, will then review the financial results of operations. Following that, we will be available for question and answer sessions. Also joining us today to address your questions is Dr. Eric Su, Senior Vice President of Preclinical Research and Development. Please be advised that certain statements in the following conference call, including expectations for in-meds business operations, cli...